meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus lenvatinib
title
Standard of Care (SoC)
title
KEYNOTE-775, 2023 NCT03517449 endometrial cancer 411/416
LEAP-001/ENGOT-en9, 2024 NCT03884101 endometrial cancer -9/-9
Pathology:
endometrial cancer;
endometrial cancer
KEYNOTE-775, 2023
LEAP-001/ENGOT-en9, 2024
pembrolizumab plus lenvatinib
2
T1
T1
Standard of Care (SoC)
0
T0
T0